Patent application number | Description | Published |
20090176795 | Enhanced delivery of antifungal agents - Tetrahydrofuran antibiotics formulated with certain diacylglycerol-poltethyleneglycol (DAG-PEG) lipids have increased water solubility and bioavailabilty. PEG-12 GDO, PEG-12 GDLO, PEG-12 GDM and PEG-12 GDP are particularly suitable for forming liposomes that incorporate tetrahydroflurans in the bilayer. | 07-09-2009 |
20090291132 | Enhanced delivery of antifungal agents - Tetrahydrofuran antibiotics formulated with certain diacylglycerol-poltethyleneglycol (DAG-PEG) lipids have increased water solubility and bioavailability. PEG-12 GDO, PEG-12 GDLO, PEG-12 GDM and PEG-12 GDP are particularly suitable for forming liposomes that incorporate tetrahydrofurans in the bilayer. | 11-26-2009 |
20100076209 | PEG-lipid conjugates for liposomes and drug delivery - New diacylglycerol-polyethylene glycol (DAG-PEG) conjugates are described. A variety of linkers between the PEG chain and glycerol backbone of the DAG-PEGs may be selected to optimize liposomal formulations of pharmaceuticals and cosmetics. | 03-25-2010 |
20100143455 | Triazole antifungal agents - New triazole antifungal agents having C6S7 or S6C7 bridges are disclosed. These triazoles provide alternatives to existing antifungals in terms of formulation, bioavailability and activity. | 06-10-2010 |
20100210518 | Peg-lipid conjugates for increasing the solubility of drug compounds - Diacyl lipid-polymer conjugates are used to enhance the solubility of lipophilic drugs in aqueous solution. The conjugates comprise a backbone, two lipophilic acyl groups and a hydrophilic polymer. | 08-19-2010 |
20100240883 | Lipid-drug conjugates for drug delivery - New prodrugs are derived from highly water soluble parent drugs that exist as primary or secondary amines in their parent form. Lipophilic carrier groups are bonded to the parent drug via an amide linkage with additional linker elements between the amide group and the carrier group. | 09-23-2010 |
20100330033 | Protein-carrier conjugates - The invention provides compositions and methods for covalent attachment of polymer and lipid carriers to therapeutic proteins to form carrier-protein conjugates having linkers between the carrier and protein portions of the conjugates. The linkers are selected to minimize steric effects. The linkers reduce the shielding effect of the carrier on the therapeutic protein and also allow better access for enzymatic or chemical cleavage of the carbamate bond. The linkers attach to the therapeutic protein via a carbamate bond and are either directly adjacent to the carbamate bond or are separated by a single carbon having a nitrogen side chain. Such linkers are solely comprised of carbon, sulfur and hydrogen and are between four and ten atoms (either C or S) in length. | 12-30-2010 |
20110033527 | Opthalmic compositions of cyclosporin - Lipid-polymer compounds are used to solubilize cyclosporin. Diacylglycerol-polyethyleneglycols (DAG-PEGs) are especially useful in this regard. A preferred embodiment of the invention is an aqueous solution of cyclosporin suitable for opthalmic use. | 02-10-2011 |
20110040113 | Pure PEG-lipid conjugates - Syntheses of polyethyleneglycol (PEG)-lipid conjugates are disclosed. Such syntheses involve stepwise addition of small PEG oligomers to a glycerol backbone until the desired chain size is attained. Polymers resulting from the syntheses are highly monodisperse. The present invention provides several advantages such as simplified synthesis, high product yield and low cost for starting materials. The present synthesis method is suitable for preparing a wide range of conjugates. | 02-17-2011 |
20110064791 | Self forming, thermodynamically stable liposomes and their applications - Certain diacylglycerol-polyethyleneglycol (DAG-PEG) lipids are especially useful for forming thermodynamically stable liposomes. Such liposomes are useful for a variety of purposes, including the delivery of therapeutic agents. | 03-17-2011 |
20110082067 | Nanotechnology for spilled oil encapsulation, remediation and recovery - Diacylglycerol PEGs (DAG-PEGs) are used remediate oil contaminations. DA-PEGs encapsulate the oil into lipsomes in an aqueous environment. The lipsomes sequester the oil from causing damage. | 04-07-2011 |
20110105387 | Method of treatment with rapamycin - The invention comprises a method of treatment using an oral capsule dose of rapamycin formulated with PEG-lipids. Two types of PEG-lipids are used in the formulation. A solubilizing agent dissolves the rapamycin, and solidifying agent is used to convert the solution of rapamycin/solubilizing agent to a more solid form. | 05-05-2011 |
20120232169 | HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES - (PEG)-lipid conjugates and methods of preparation are disclosed herein. Methods of preparation may involve stepwise addition of small PEG oligomers to a glycerol backbone until a desired chain size is attained. Polymers resulting from the syntheses may be highly monodisperse. The resulting polymers may comprise branched polyethyleneglycol (PEG)-lipid conjugates. The present disclosure may provide several advantages such as simplified synthesis, high product yield and low cost for starting materials. The present synthesis method may be suitable for preparing a wide range of conjugates such as PEG lipid conjugates having a glycerol-like central backbone covalently attached to two or more monodisperse PEG chains and a lipid comprising a range of diesters made from fatty acids or bile acids. | 09-13-2012 |
20130129815 | LIPOSOMAL FORMULATION FOR ORAL ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA GEL CAPSULE - The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation in a gel cap. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa. | 05-23-2013 |